I was excited to learn recently of a new cancer drug called olaparib. Not only does olaparib show promise by targetting specific cancer cells (thus sparing healthy ones), its inrended use will be for hereditary cancer caused by faulty BRCA1 and BRCA2 genes – which includes some colon, prostate and ovarian cancers. These are some of the cancers faced by Ostomyland Members.

So far the small scale patient trial has shown remarkable benefit for patients with breast, ovarian and prostate cancer. The next step is to extend the trial.

Breakthrough Breast Cancer scientists think that if future trials are positive, olaparib could offer hope to patients with certain types of breast and ovarian cancers that are currently hard to treat. Scientists are already suggesting that it could be used for other forms of cancer with similar characteristics and open the door to a new generation of cancer treatments using the same approach.

They hope that olaparib may also work for some people who do not have a BRCA gene fault.

For more information see these two web articles:
Breakthrough Breast Cancer Research Centre Pioneering Work Leads To Patient Trial Of New Generation Cancer Drug

Can you tell me about olaparib?

Comments are closed.